Beckman Coulter, MeMed partner to expand access to MeMed BV test

2023-02-01
引进/卖出免疫疗法诊断试剂
Beckman Coulter has been gained rights to develop and jointly market the MeMed BV test on its Access Family of Immunoassay Analyzers The headquarters of Beckman Coulter in California. (Credit: Coolcaesar from Wikimedia Commons) Beckman Coulter Diagnostics, a part of Danaher, and MeMed have announced a partnership to co-develop and commercialise the latter’s MeMed BV test, a host immune response diagnostic. MeMed, which is based in Israel, has designed the MeMed BV test to distinguish between
bacterial and viral infections
. According to the terms of the collaboration, Beckman Coulter has been given rights to develop and jointly market the MeMed BV test on its Access Family of Immunoassay Analyzers. Beckman Coulter president Julie Sawyer Montgomery said: “We are thrilled to be partnering with MeMed to make this novel test available to millions of patients through our Access Family of Immunoassay Analyzers. “The ability to distinguish between
bacterial and viral infections
early in the diagnostic process has significant potential to impact patient care, as well as combat antimicrobial resistance.” MeMed has developed the BV test to support the management of patients with acute infections in a variety of clinical settings, including emergency departments. The MeMed BV test utilises machine learning for integrating measurements of three important host-immune proteins TRAIL,
IP-10
, and CRP to produce a score that indicates the risk of
bacterial or viral infections
. The test’s performance is said to have been verified using MeMed Key, a compact  immunoassay platform in over 20,000 patients in various blinded validation studies and in real-world use, said Beckman Coulter. MeMed BV on MeMed Key has received US Food and Drug Administration (FDA) clearance, CE-marking, as well as Israeli Ministry of Health’s approval. MeMed CEO and co-founder Eran Eden said: “Our vision for MeMed BV is that it becomes standard of care, enabling significant improvements in patient management to address the urgent global antimicrobial resistance threat. “We believe that forging a strategic alliance with an industry leader, such as Beckman Coulter, will expedite the realisation of this vision and support better clinical, operational, and financial outcomes for healthcare systems globally.”
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
病毒感染
靶点
CXCL10
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。